SAFETY AND EFFECTIVENESS OF IV THROMBOLYSIS IN RETINAL ARTERY OCCLUSION (ID 918)
- Philipp Baumgartner (Switzerland)
- Valerian Altersberger (Germany)
- Stefan T. Engelter (Switzerland)
- Henrik Gensicke (Switzerland)
- Elena Ardila-Jurado (Switzerland)
- Georg Kägi (Switzerland)
- Alexander Salerno (Switzerland)
- Patrik Michel (Switzerland)
- Kiran Gopisingh (Netherlands)
- Paul J. Nederkoorn (Netherlands)
- Jan F. Scheitz (Germany)
- Christian Nolte (Germany)
- Mirjam R. Heldner (Switzerland)
- Marcel Arnold (Switzerland)
- Lucie Della Schiava (France)
- Charlotte Cordonnier (France)
- Christian Hametner (Germany)
- Peter Ringleb (Germany)
- Kook Lucas (Switzerland)
- Andreas R. Luft (Switzerland)
- Susanne Wegener (Switzerland)
Abstract
Group Name
ThRombolysis in Ischemic Stroke Patients (TRISP) collaborators
Background And Aims
Acute retinal artery occlusion (RAO) can lead to irreversible blindness if not treated rapidly. Intravenous thrombolysis (IVT) is used in clinical practice; however, data about its effectiveness and safety is limited. Here, we retrospectively analyzed the outcome of CRAO patients treated with IVT from nine European stroke centers.
Methods
From the multicenter IVT database ThRombolysis in Ischemic Stroke Patients (TRISP), we compared the visual outcome of IVT and non-IVT treated RAO patients from 2014-2021. Visual acuity (VA) was obtained at baseline and within 3 months. Outcomes were any visual improvement, favorable VA (> 0.2 in decimal) and safety (symptomatic intracranial hemorrhage (sICH) according to ECASS II criteria, asymptomatic intracranial hemorrhage (ICH) and major extracranial bleeding).
Results
We identified 56 IVT and 141 non-IVT patients with CRAO. We excluded 106 patients with missing information about VA. Median IVT symptom-to-needle time was 235min (25th/75th percentile: 216, 306). At baseline, IVT patients had more severely impaired VA. At follow up, VA improved in 27/48 (56%) IVT patients and in 17/43 (39%) non-IVT patients. Rates of favourable VA recovery were 12/48 (25%) in IVT and 21/43 (48%) in non-IVT patients. We observed no sICH, two asymptomatic ICH (4%) and one major extracranial bleeding (2%) after IVT and none in non-IVT patients.
Conclusions
Our study provides real-life data from a large European cohort of IVT treated RAO patients. IVT seems safe and may improve VA in RAO patients. However, rates of satisfactory visual outcomes remain low. To facilitate further studies, outcome assessment in RAO patients should be standardised.
Trial Registration Number
Not applicable
